About
Bio-Neuroscience convenes an outstanding mix of innovators, CEOs and decision-makers in CNS neuroscience drug development from the leading biotech companies, investors and pharma companies in the sector
Insight - Access - Engagement - Impact
Profy Countdown Timer: Visible on Live site
Premier Gathering of Innovators
The one event which convenes a high-level, by-invitation, boutique gathering of thought leaders, innovators, CEOs and senior decision-makers from the leading stakeholders groups in CNS neuroscience drug development.
The business of CNS Neuroscience drug development.
Where CEOs and C-level executives of the hottest companies come together with industry leaders, decision-makers, patient organizations, funders and the leading investors in CNS neuroscience drug development to dive into the the issues that matter most to stakeholders.
Elevating Engagement and Collaboration
A unique level of sustained high-quality discussion, access, engagement and partnering in a truly curated summit unlike other events.
Broadreach Summits - What Participants Say
A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.
Pawel Swieboda
Director General
A masterfully organized holistic view of developments in policy, clinical and business strategy, patient care and investment.
Pawel Swieboda
Director General
Vision
Convening the full value chain to disrupt silos and curate highly interactive, multi-disciplinary, cross-industry, and multi-stakeholder discussions of opportunities, challenges, hurdles and ways forward.
Drive transformational connections, discussion and partnering for startups and growth companies.
Deliver insight, access, engagement and partnering to foster innovation and accelerate value creation.
Contribute to meaningful improvement in healthcare outcomes and positive impact for patients and society.
Get feedback and advice on your business, your objectives and your core challenges from leading innovators, investors and industry leaders in CNS neuroscience drug development.
Why Now?
Now is the time for CNS neuroscience drug development. We have entered a time when truly rational drug discovery and development is possible and where new discoveries, tools, technologies, biomarkers and insights enable improved development.
Investor and industry interest is booming, yet key challenges remain that can only be addressed by bringing together the leading translational research, clinicians, entrepreneurs, CEOs, CSOs and CMOs from the leading biotech companies, with relevant therapeutic area and business development heads from big pharma and large biotech, as well as the Partners and Directors heading neuroscience investment at the most active and important investment funds.
The 2024 pilot edition established Bio-Neuroscience as a unique, high-level and interactive summit providing participants exceptional value in terms of the experience, insight, access and impact.
Meet the Advisory Board
Advisory Board
Stacie Weninger
Executive Director - F-Prime Biomedical Research Initiative
Hakan Goker
Managing Director, Head of Healthcare & Life Sciences - M-Ventures
Joachim Scholpp
Global Head Translational Medicine CNS & Emerging Areas - Boehringer Ingelheim
Sourav Kole
Managing Director - Dolby Family Ventures
Rita Balice-Gordon
Chief Executive Officer - Muna Therapeutics
Martien Kas
President - European College of NeuroPsychopharmacology (ECNP)
Kalpana Merchant
Member of the Board - Envisagenics, President & CEO - Transthera, Adjunct Prof. Northwestern University Feinberg School of Medicine
Kees Been
Chief Executive Officer - Kynexis Therapeutics Inc.
Pieter van Bokhoven
Chief Scientific Officer - IXA Amsterdam Neuroscience UMC
Juan Carlos Lopez
Managing Director - Haystack Science, formerly Chief Editor - Nature Medicine & Founding Editor - Nature Reviews Neuroscience
Andrea Soto Padilla
Business Development - Amsterdam UMC
Mark Treherne
Chairperson - Monument Therapeutics, Commercial Scientists, Investor, Chair of Talisman Therapeutics, Ubiquent, NuVision Biotherapies
Meet the Speakers - Check back for regular updates and additions.
Proudly convening leading speakers and stakeholders from across the sector
Steve Brannan
FIRESIDE CHAT - Former Chief Medical Officer - Karuna Therapeutics
Jan Klatt
Senior Vice President, Head of the Development Unit Neurology & Immunology - Merck KGaA
Hugh Nuthall
Executive Director, Search & Evaluation, Neuroscience - Eli Lilly
Nawal Roy
Founder & CEO - Holmusk
Leonard van den Berg
Chair - TRICALS, Founder & Chair - ENCALS, Founder & Director - ALS Centrum Nederland
Tarek Samad
Senior Vice President & Global Head of Research - Lundbeck
Philip Scheltens
Head, Dementia Fund, Partner - EQT Life Sciences
Frédéric Destébecq
Executive Director - European Brain Council (EBC) & European Brain Foundation (EBF)
Steven Biesmans
Principal - UCB Ventures
Sunitha Malepati
Founder - Buffalo Initiative, Vice President - CACNA1A Foundation
Robert Thorne
KEYNOTE SPEAKER - Denali Fellow - Denali Therapeutics
Adjunct Associate Professor - University of Minnesota
President - International Brain Barriers Society (IBBS)
Claire Leurent
Managing Director - AbbVie Ventures
Raúl Martín-Ruiz
Partner - Ysios Capital
Klaus Dugi
CEO - Vandria SA
Alexander Natz
Secretary General - European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
Husseini K Manji, MD, FRCPC
KEYNOTE SPEAKER - Professor - Oxford University, Co-chair - UK Government Mental Health Mission
Allyson Berent
Chief Scientific Officer - Foundation for Angelman Syndrome Therapeutics (FAST)
Thomas Michael Thestrup
Senior Principal - Angelini Ventures
Stevin Zorn
President & CEO - MindImmune Therapeutics
Bruce Leuchter
President & CEO - Neurvati Neurosciences
Pablo Sardi
Global Head, Rare & Neurologic Diseases Therapeutic Area - Sanofi
Jacopo Andreose
CEO - Angelini Pharma S.p.A.
Clara Campàs
Managing Partner & Co-Founder - Asabys Partners
Brigit de Jong
Neurologist - Amsterdam University Medical Center
Vikas Sharma
Chief Business Officer - QurAlis
Presenting Companies
Benefit From
Pre-summit guidance and feedback on your deck.
A pre-summit dry-run presentation with feedback.
5 minute presentation followed by 5 minutes Q&A with an expert panel of relevant investors and industry: In the plenary session.
Join a curated selection of the most innovative, promising and high potential companies with potential to transform CNS neuroscience drug development & treatment. Selection is by excellence and potential, not by price tag! There is no cost to present beyond the regular startup or private company registration fees.
Your Poster in the networking area.
Meeting space in the main networking area to facilitate additional post presentation discussion in the 45 minute networking break immediately following your presentation session.
2 Days of sustained engagement with the best network of innovators, investors, industry leaders & decision-makers in CNS neuroscience drug development.
Option to add an exclusive company exhibition stand. There is no requirement to sponsor or exhibit; these exist as separate options each with their own unique range of benefits, however these will not have any impact on the selection of presenting companies.
Who's Coming
Two days of sustained, interactive discussion, networking and partnering with:
Industry Leaders
Industry decison-makers, Heads of Therapeutic Area, Scouting, Alliance Management, Business Development & Licensing, Strategy & Portfolio from pharma & large biotech.
Key Opinion Leaders
Key Opinion Leaders from research, clinical development & care, strategy, finance, business development, licensing, regulatory, market launch & M&A.
Founders & CEOs
Founders, CEOs & C-Level from the most innovative and hottest CNS neuroscience companies leading innovation & deals in the sector.
Government & NGOs
Public funding bodies, policy makers, public agencies, societies, associations & NGOs in neuroscience, agencies, regulatory bodies.
Investors
Managing Partners & Partners from the most active CNS Neuroscience investing VC funds, Managing Directors & Directors of the leading Corporate Venture, Private Equity and Family Office Funds, Foundations & more.
Patients
A selected group of leading patient driven companies, non profits, foundations, associations and charities focused on the development of novel therapies for patients.
Venue
Bio-Neuroscience brings together an outstanding mix of leaders and decision-makers in CNS Neuroscience drug development.
Hotel Jakarta
Javakade 766, 1019 SH Amsterdam,
Netherlands
Bio-Neuroscience takes place at Hotel Jakarta, a sustainable modern hotel designed as a green oasis on the IJ river. The selection of the Hotel Jakarta Amsterdam as the new venue was made based on its central location, comfortable rooms and green atmosphere, and a setup which is well suited for the highly interactive but boutique interactive nature of Bio-Neuroscience, including improved plenary spaces, natural light, and increased networking space for business development and networking.
Get In Touch
Access - Insight - Engagement - Impact
Nominate a speaker
Apply to present your company or technology
Enquire about sponsorship & exhibition opportunities
Copyright © 2023. All rights reserved. Broadreach Global LLC.
Terms Of Use & Privacy